V Square Quantitative Management LLC Boosts Stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

V Square Quantitative Management LLC grew its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 8.4% during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 5,697 shares of the medical equipment provider’s stock after buying an additional 441 shares during the quarter. V Square Quantitative Management LLC’s holdings in Zimmer Biomet were worth $618,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of ZBH. Chicago Partners Investment Group LLC lifted its position in shares of Zimmer Biomet by 3.3% during the fourth quarter. Chicago Partners Investment Group LLC now owns 2,894 shares of the medical equipment provider’s stock worth $349,000 after purchasing an additional 92 shares during the last quarter. North Star Investment Management Corp. grew its stake in Zimmer Biomet by 16.6% in the 1st quarter. North Star Investment Management Corp. now owns 669 shares of the medical equipment provider’s stock worth $88,000 after acquiring an additional 95 shares in the last quarter. First Bancorp Inc ME raised its stake in shares of Zimmer Biomet by 5.3% during the first quarter. First Bancorp Inc ME now owns 1,970 shares of the medical equipment provider’s stock valued at $260,000 after acquiring an additional 100 shares in the last quarter. Ballentine Partners LLC boosted its holdings in shares of Zimmer Biomet by 2.6% in the first quarter. Ballentine Partners LLC now owns 3,957 shares of the medical equipment provider’s stock valued at $522,000 after purchasing an additional 100 shares during the period. Finally, Romano Brothers AND Company increased its holdings in Zimmer Biomet by 1.1% during the 1st quarter. Romano Brothers AND Company now owns 9,514 shares of the medical equipment provider’s stock worth $1,256,000 after purchasing an additional 100 shares during the period. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. Royal Bank of Canada dropped their price target on Zimmer Biomet from $140.00 to $130.00 and set an “outperform” rating on the stock in a research report on Thursday, August 8th. The Goldman Sachs Group assumed coverage on shares of Zimmer Biomet in a research report on Thursday, May 30th. They set a “neutral” rating and a $129.00 target price on the stock. Argus raised shares of Zimmer Biomet from a “hold” rating to a “buy” rating and set a $150.00 price target for the company in a research report on Tuesday, May 21st. Oppenheimer dropped their target price on Zimmer Biomet from $155.00 to $145.00 and set an “outperform” rating on the stock in a research report on Thursday, August 8th. Finally, Robert W. Baird reduced their price target on Zimmer Biomet from $155.00 to $145.00 and set an “outperform” rating for the company in a research report on Thursday, August 8th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, Zimmer Biomet presently has a consensus rating of “Hold” and a consensus price target of $127.67.

Zimmer Biomet Stock Performance

Shares of NYSE ZBH traded down $0.95 during midday trading on Wednesday, reaching $108.36. 530,021 shares of the stock were exchanged, compared to its average volume of 1,495,725. The company has a quick ratio of 0.63, a current ratio of 1.29 and a debt-to-equity ratio of 0.31. The firm has a 50-day simple moving average of $108.78 and a two-hundred day simple moving average of $118.39. Zimmer Biomet Holdings, Inc. has a twelve month low of $102.00 and a twelve month high of $133.90. The firm has a market cap of $22.07 billion, a price-to-earnings ratio of 23.66, a PEG ratio of 1.88 and a beta of 1.01.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Wednesday, August 7th. The medical equipment provider reported $2.01 earnings per share for the quarter, topping analysts’ consensus estimates of $1.99 by $0.02. Zimmer Biomet had a net margin of 13.25% and a return on equity of 12.86%. The business had revenue of $1.94 billion during the quarter, compared to the consensus estimate of $1.94 billion. During the same quarter in the prior year, the firm posted $1.82 earnings per share. The company’s revenue was up 3.9% compared to the same quarter last year. As a group, analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.08 EPS for the current fiscal year.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.